<DOC>
	<DOCNO>NCT01077297</DOCNO>
	<brief_summary>Multicenter , Open-label , Non-comparative , Proof-of-concept , Phase 2a Study Evaluate Effect Single Infusion Tezosentan Pulmonary Vascular Resistance Patients With Stable , Chronic Pulmonary Arterial Hypertension , Currently Not Treated With Endothelin Receptor Antagonists , Phosphodiesterase-5 Inhibitors Prostacyclines</brief_summary>
	<brief_title>Tezosentan Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>1 . Signed informed consent 2 . Male female patient 18 year age old 3 . Patients PAH accord one follow subgroup Venice Classification Group 1 : Idiopathic ( iPAH ) , Familial/heritable ( FPAH ) , Associated ( APAH ) collagen vascular disease 4 . Modified NYHA functional class IIIII 5 . Documented hemodynamic diagnosis PAH right heart catheterization Baseline : Resting mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg Resting mean PVR ≥ 240 dyn•s•cm5 Pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mmHg 1 . Patients PAH Venice Classification Groups 25 , PAH Group 1 subgroup cover inclusion criterion . 3 2 . Hypotensive patient ( systemic systolic blood pressure &lt; 100 mmHg ) 3 . Patients body weight &lt; 50 kg ( 110 lb ) 4 . Patients moderate severe hepatic impairment ( ChildPugh B C ) 5 . Patients clinically significant chronic renal insufficiency ( serum creatinine &gt; 2.5mg/dL / 221µmol/L ) 6 . Patients receive endothelin receptor antagonist ( ERA ) and/or phosphodiesterase5 ( PDE5 ) inhibitor within 28 day Baseline 7 . Patients receive prostacyclin ( epoprostenol ) prostacyclin analog ( e.g. , treprostinil , iloprost ) within 28 day Baseline 8 . Patients receive investigational drug within 28 day Baseline 9 . Patients receive cyclosporine A tacrolimus within 28 day Baseline 10 . Psychotic , addictive disorder limit ability provide inform consent comply study 11 . Life expectancy le 12 month 12 . Females lactate pregnant female use reliable method birth control ( failure rate le 1 % per year ) study least one month study drug intake 13 . Known hypersensitivity excipients drug formulation 14 . Patients positive response vasoreactivity test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>